

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert L. GARCEA et al.	Examiner:
Application No.: 10/541,895	Art Unit: 1645
Filed: July 7, 2005	Confirmation No.: 5191
For: THERAPEUTIC AND PROPHYLACTIC VACCINE FOR THE TREATMENT AND PREVENTION OF PAPILLOMAVIRUS INFECTION	

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

The Information Disclosure Statement submitted herewith is being filed before the mailing date of a first Office action on the merits.

The Examiner is requested to consider the references noted on the enclosed Form PTO/SB/08a during examination of the above-identified patent application. These references are submitted for the Examiner's consideration and are submitted pursuant to the duty of disclosure under 37 CFR § 1.56. In submitting these references, no representation is made or implied that the references are or are not material to the examination of the application. The Examiner is encouraged to make his or her own determination of materiality. In accordance with 37 CFR § 1.98(a)(2)(i) and (ii), copies of the U.S. patents and publications are not provided herewith. Copies of the foreign patents are provided herewith.


This Information Disclosure Statement is being filed before the receipt of an Office Action on the merits. No fee is believed to be necessary. However, should any fee be required,

Application No. 10/541,895
Attorney Docket No. 66888-31995

the Commissioner is authorized to charge our Deposit Account No. 06-0029 and is requested to notify us of the same.

FAEGRE & BENSON LLP

Respectfully submitted,


Roberta J. Hanson
Registration No. 51,774
Agent for Applicant
Tel.: (303) 607-3500
Fax: (303) 607-3600

Date: Feb. 16, 2006

DNVR1:60303386.01

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/541,895
				Filing Date	July 7, 2005
				First Named Inventor	GARCEA, Robert L
				Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	66888-319995

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ ; Number ⁴ ; Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		PCT -			
		-			
		-			

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner Initials*	Cite No. ¹	
		"Expression of the Human Papillomavirus Type 11 L1 Capsid Protein in <i>Escherichia coli</i> : Characterization of Protein Domains involved in DNA Binding and Capsid Assembly" by Li et al., Journal of Virology, Apr. 1997, Vol. 71, No. 4, p. 2988-2995
		"Self-Assembly of Human Papillomavirus Type 1 Capsids by Expression of the L1 Protein Alone or by Coexpression of the L1 and L2 Capsid Proteins" by Hagensee et al., Journal of Virology, Jan. 1993, Vol 67, No. 1, p. 315-322
		"Papillomavirus Capsid Protein Expression in <i>Escherichia coli</i> : Purification and Assembly of HPV11 and HPV 16 L1" by Chen et al., J. Mol. Biol. (2001) 307, 173-182
		"The Nine C-Terminal Amino Acids of the Major Capsid Protein of the Human Papillomavirus Type 16 are Essential for DNA Binding and Gene Transfer Capacity" by Touze et al., FEMS Microbiology Letters 189 (2000) 121-127.
		"L1 Interaction Domains of Papillomavirus L2 Necessary for Viral Genome Encapsidation" BY Okun et al., Journal of Virology, May 2001, Vol. 75, No. 9, p. 4332-4342
		"Efficient Self-Assembly of Human Papillomavirus Type 16 L1 and L1-L2 into Virus-Like Particles" by Kimbauer et al., Journal of Virology, Dec. 1993, Vol. 67, No. 12, p. 6929-6936.

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.